Gawronski Catherine A, Gawronski Kristen M
University at Buffalo School of Pharmacy, Buffalo, NY, USA.
Lake Erie College of Osteopathic Medicine School of Pharmacy, Erie, PA, USA
Ann Pharmacother. 2016 Aug;50(8):680-4. doi: 10.1177/1060028016647066. Epub 2016 May 4.
To review the evidence on vitamin A supplementation (VAS) and bronchopulmonary dysplasia (BPD) in extremely-low-birth-weight infants. We also discuss the impact of a vitamin A shortage on BPD rates.
A PubMed search inclusive of dates 1946 to March 2016 was performed using the search terms bronchopulmonary dysplasia, chronic lung disease (CLD), and vitamin A STUDY SELECTION AND DATA EXTRACTION: All English-language studies were evaluated. Only those investigating VAS by intramuscular administration were included.
A total of 6 studies were evaluated. Additionally, a report on the incidence of BPD during a national shortage was reviewed. Investigators found mixed results with VAS and incidence of CLD or death in a varying number of neonates. In the largest evaluation, investigators found a statistically significant decrease in the rate of death or BPD: 55% in the VAS group versus 62% in the placebo group. The number needed to treat to prevent 1 case of BPD was 15 infants. Few studies found an increased incidence of adverse events following VAS. A report over a 2-year shortage period found that whereas the rate of VAS declined dramatically, BPD rates remained stable. This large observational evaluation calls into question the place of vitamin A in BPD prevention.
VAS has been identified as a strategy to decrease the incidence of BPD. Initial large-scale prospective evaluations have shown clear benefit of VAS in reducing the incidence of CLD or death. However, changing definitions of BPD and implementation of noninvasive ventilation strategies limit the application of early studies. During a drug shortage, VAS declined dramatically, but BPD rates remained stable. With concerns of sepsis and necrotizing enterocolitis in small-scale studies, and in light of the recent shortage evidence, further evaluations are necessary before VAS can be recommended as a cornerstone of BPD prevention.
回顾关于极低出生体重儿维生素A补充(VAS)与支气管肺发育不良(BPD)的证据。我们还将讨论维生素A缺乏对BPD发生率的影响。
使用搜索词支气管肺发育不良、慢性肺病(CLD)和维生素A,对1946年至2016年3月期间的PubMed进行了检索。
对所有英文研究进行了评估。仅纳入那些通过肌肉注射进行VAS研究的文献。
共评估了6项研究。此外,还查阅了一份关于全国维生素A短缺期间BPD发生率的报告。研究人员发现,VAS与不同数量新生儿的CLD发生率或死亡率之间的结果不一。在规模最大的评估中,研究人员发现死亡或BPD发生率有统计学显著下降:VAS组为55%,安慰剂组为62%。预防1例BPD所需治疗的婴儿数为15名。很少有研究发现VAS后不良事件发生率增加。一份关于为期2年短缺期的报告发现,虽然VAS率大幅下降,但BPD率保持稳定。这项大规模观察性评估对维生素A在BPD预防中的地位提出了质疑。
VAS已被确定为降低BPD发生率的一种策略。最初的大规模前瞻性评估显示,VAS在降低CLD或死亡率方面有明显益处。然而,BPD定义的变化和无创通气策略的实施限制了早期研究的应用。在药物短缺期间,VAS率大幅下降,但BPD率保持稳定。鉴于小规模研究中对败血症和坏死性小肠结肠炎的担忧,以及近期的短缺证据,在VAS被推荐作为BPD预防的基石之前,有必要进行进一步评估。